Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from a clinical evaluation of its lead program in gout, NU1618, and pre-clinical data describing the mechanism of action for the tranilast component of NU1618, have been accepted for...
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that a phase 2a study of NU1618, the company's lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia. "This successful...